title: Accelerated endothelialization with a polymer-free sirolimus-eluting antibody-coated stent.
abstract: Drug-eluting stents have shown an impressive reduction of in-stent restenosis for many years. However, stent thrombosis due to incomplete/late endothelialization has raised major safety concerns. To overcome these problems, we developed for the first time a polymer-free sirolimus-eluting antibody-coated stent (PFSEACS) by combining polymer free and endothelial progenitor cell-capture pro-healing approaches. In the first phase, the stents were prepared by loading sirolimus on the porous outer stent surface and directly fixing the anti-CD34 antibodies without any medium carriers on the blood contacting surface. The dose and elution of sirolimus, the amount and stability of anti-CD34 antibody immobilization, and the rate of CD34+ cell capture were evaluated. In the second phase, the stents were validated in an animal model of coronary arteries in pigs. The stent was observed to start collecting endothelial progenitor cells ~2 h after stent implantation and exhibited greatly enhanced endothelialization while maintaining an excellent anti-restenosis activity comparable to the polymer-free sirolimus-eluting stents. Overall, both in vitro and in vivo evaluations indicated that novel PFSEACSs exhibited facilitated endothelialization with excellent anti-restenosis activity and thus should merit further clinical studies.
authors: State Key Laboratory of Natural and Biomimetic Drugs and Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, People's Republic of China.
authors: Zhanjiang
authors: Z
authors: Yu
authors: Huagang
authors: H
authors: Zhu
authors: Shuzheng
authors: S
authors: Lü
authors: Xiaoda
authors: X
authors: Yang
mesh_terms: D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D003331:Coronary Vessels / Q000187:drug effects / Q000276:immunology / Q000648:ultrastructure; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects* / Q000276:immunology / Q000648:ultrastructure; D008855:Microscopy, Electron, Scanning; D020123:Sirolimus / Q000008:administration & dosage*; D013552:Swine; D013556:Swine, Miniature
chemical_list: D000906:Antibodies; D020123:Sirolimus
references: Eur Heart J. 2005 Aug;26(15):1475-81
references: 15975990
references: Catheter Cardiovasc Interv. 2008 Feb 15;71(3):333-9
references: 18288747
references: J Am Coll Cardiol. 2005 May 17;45(10):1574-9
references: 15893169
references: J Am Coll Cardiol. 2006 Jul 4;48(1):193-202
references: 16814667
references: N Engl J Med. 2007 Mar 8;356(10):998-1008
references: 17296824
references: Circulation. 2007 Feb 27;115(8):1051-8
references: 17325255
references: J Interv Cardiol. 2010 Apr;23(2):101-8
references: 20236214
references: J Am Coll Cardiol. 2007 Feb 6;49(5):616-23
references: 17276188
references: JACC Cardiovasc Interv. 2009 Apr;2(4):284-90
references: 19463438
references: J Am Coll Cardiol. 2010 Aug 31;56(10 Suppl):S43-78
references: 20797503
references: N Engl J Med. 2009 May 7;360(19):1933-45
references: 19420363
references: Circulation. 2007 Mar 20;115(11):1440-55; discussion 1455
references: 17344324
references: J Mater Sci Mater Med. 2008 Sep;19(9):3115-21
references: 18414999
references: Biomaterials. 2006 Nov;27(32):5588-95
references: 16879865
references: Biomaterials. 2010 May;31(14):4017-25
references: 20149438
references: JACC Cardiovasc Interv. 2010 Jan;3(1):68-75
references: 20129572
references: Circ Cardiovasc Interv. 2010 Jun 1;3(3):257-66
references: 20442358
references: EuroIntervention. 2008 Aug;4 Suppl C:C67-71
references: 19202700
references: Biomaterials. 2009 Feb;30(4):632-7
references: 18990438
references: J Am Coll Cardiol. 2006 May 2;47(9):1786-95
references: 16682302
references: Ann Biomed Eng. 2000 Apr;28(4):386-98
references: 10870895
references: Acta Biomater. 2009 May;5(4):945-58
references: 19111513
references: J Am Coll Cardiol. 2008 Jul 29;52(5):333-42
references: 18652940